Inge M. Haeck

Delft, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry.

Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry.

Journal: Expert opinion on biological therapy

Published: July 13, 2026

Dupilumab in prurigo nodularis: 52-week effectiveness and safety from the prospective multicenter BioDay registry.

Dupilumab in prurigo nodularis: 52-week effectiveness and safety from the prospective multicenter BioDay registry.

Journal: Journal of the American Academy of Dermatology

Published: March 20, 2026

Dupilumab in prurigo nodularis: 52-Week effectiveness and safety from the prospective multicenter BioDay registry.

Dupilumab in prurigo nodularis: 52-Week effectiveness and safety from the prospective multicenter BioDay registry.

Journal: Journal of the American Academy of Dermatology

Published: March 20, 2026

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.

Journal: The Lancet regional health. Europe

Published: January 29, 2026

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 15, 2026

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis.

Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: December 22, 2025

Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment.

Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment.

Journal: Expert opinion on biological therapy

Published: December 01, 2025

A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany.

A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany.

Journal: Acta dermato-venereologica

Published: November 26, 2025

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.

Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.

Journal: Allergy

Published: July 29, 2025

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 30, 2025

Topical Steroid Withdrawal: Perspectives of Dutch Healthcare Professionals.

Topical Steroid Withdrawal: Perspectives of Dutch Healthcare Professionals.

Journal: Acta dermato-venereologica

Published: June 24, 2025

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: December 19, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026